Explore the latest developments concerning Tirzepatide in Obesity:.
Tirzepatide in Obesity: No AF Link but Arrhythmia Risk Noted
In adults with overweight or obesity, tirzepatide was not associated with increased odds of atrial fibrillation (AF) or atrial arrhythmia. Higher odds of any arrhythmia were observed, although event rates remained low and the evidence was not conclusive.
"Although no clear association with AF or atrial arrhythmia was observed, the effect estimates for any arrhythmias suggested higher odds with tirzepatide. Because arrhythmias were not prespecified endpoints in most trials and event counts were low, these findings should be considered exploratory," the researchers wrote.
The study was led by Ensieh S. Mansouri, MD, of Tehran University of Medical Sciences in Tehran, Iran. It was published online on September 9 in the Journal of the American Heart Association.
2-Slice Toaster with Precision Control 6 Shade Settings Extra Wide Slots Countdown Timer Self-Centering Guides Bagel Defrost
The dynamic landscape of current events often brings forth significant discussions. Monitoring these developments provides crucial insights.
For more detailed information, explore updates concerning Tirzepatide in Obesity:.
Leave a Reply